Harvard Bioscience Revenue, Profits - HBIO Annual Income Statement

Add to My Stocks
$4.7 $0.15 (3.3%) HBIO stock closing price Feb 16, 2018 (Closing)

Financial analysis of Harvard Bioscience involves more than just checking the Harvard Bioscience stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 108.66M to 104.52M and how operating and non operating activities have impacted the HBIO stock. The operating expenses as shown in the Harvard Bioscience profit and loss statement for 2016 total to $51.4M. This line item shows that the operating expenses has increased compared with last year. Also check: Harvard Bioscience assets and Harvard Bioscience free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201620152014201320122011201020092008
Harvard Bioscience Revenues or Net Sales
104.52M108.66M108.66M105.17M111.17M108.86M108.17M85.77M88.04M
Cost Of Goods Sold (COGS)56.1M59.94M59.31M57.47M58.75M58.6M56.4M44.08M45.89M
Harvard Bioscience Gross Profit
48.41M48.72M49.34M47.69M52.41M50.26M51.77M41.68M42.15M
Research & Development Expense5.39M6.42M4.88M4.15M7.32M5.43M4.7M4.39M4.04M
Selling General & Admin Expense43.29M41.19M35.26M39.41M39.17M36M34.48M27.38M27.66M
Income Before Depreciation Depletion Amortization-0.27M1.1M9.19M4.12M5.91M8.82M12.58M9.89M10.44M
Depreciation Depletion Amortization2.72M2.81M2.57M2.59M2.75M2.74M2.36M1.84M1.96M
Non Operating Income--1.04M-1.21M-0.14M-0.35M-0.78M-2.03M-0.44M
Interest Expense---------
Harvard Bioscience Pretax Income
-3.07M-3.6M4.41M-2.22M4.54M9.56M9.81M7.65M
Provision for Income Taxes1.22M15.43M2.06M-0.28M---9.45M2.67M2.24M
MinorityInterest---------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-4.3M-19.03M2.35M-1.53M3.81M19.01M7.13M5.41M
Extraordinary Items & Discontinued Operations----2.55M-----3.73M
Harvard Bioscience Profit/ Loss (Net Income)
-4.3M-19.03M2.35M-1.83M2.37M3.81M19.01M7.23M1.67M
Average Shares used to compute Diluted EPS34.21M33.59M32.17M31.91M29.54M29.82M29.41M29.95M31.35M
Average Shares used to compute Basic EPS34.21M33.59M32.17M30.38M28.8M28.45M28.97M29.65M30.88M
Income Before Nonrecurring Items1.68M1.65M7.49M5.3M3.33M5.41M7.73M6.34M6.65M
Income from Nonrecurring Items-5.99M-20.69M-5.14M-4.58M-1.79M-1.6M11.38M--1.24M
Harvard Bioscience Earnings Per Share Basic Net
-0.13-0.570.07-0.060.080.130.660.240.05
Harvard Bioscience Earnings Per Share Diluted Net
-0.13M-0.57M--0.06M-----
EPS Diluted Before Nonrecurring Items0.050.050.230.160.110.180.260.210.21
Preferred Dividends Acc Pd---------
Dividends Common---------
Dividend Per Share Common0.000.000.001.350.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

It is very helpful to read a report on Harvard Bioscience stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Harvard Bioscience revenue chart implies that the company is growing. It has not been the case with Harvard Bioscience. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: Most businesses like Harvard Bioscience try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The HBIO financials along with Harvard Bioscience historical stock prices provide a lot of details about the firm.

Harvard Bioscience Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
1.62
Dividend Yield
0%